| Literature DB >> 26478227 |
Anne Zemella1, Lena Thoring1, Christian Hoffmeister1, Stefan Kubick2.
Abstract
From its start as a small-scale in vitro system to study fundamental translation processes, cell-free protein synthesis quickly rose to become a potent platform for the high-yield production of proteins. In contrast to classical in vivo protein expression, cell-free systems do not need time-consuming cloning steps, and the open nature provides easy manipulation of reaction conditions as well as high-throughput potential. Especially for the synthesis of difficult to express proteins, such as toxic and transmembrane proteins, cell-free systems are of enormous interest. The modification of the genetic code to incorporate non-canonical amino acids into the target protein in particular provides enormous potential in biotechnology and pharmaceutical research and is in the focus of many cell-free projects. Many sophisticated cell-free systems for manifold applications have been established. This review describes the recent advances in cell-free protein synthesis and details the expanding applications in this field.Entities:
Keywords: cell-free protein synthesis; eukaryotic and prokaryotic lysates; membrane proteins; post-translational modifications; vesicles
Mesh:
Substances:
Year: 2015 PMID: 26478227 PMCID: PMC4676933 DOI: 10.1002/cbic.201500340
Source DB: PubMed Journal: Chembiochem ISSN: 1439-4227 Impact factor: 3.461
Comparison of different CFPS systems.
| System | Advantages | Disadvantages | Applications | Refs. |
|---|---|---|---|---|
| 1. High protein yield 2. Simple cultivation and fast cell growth and lysate preparation 3. Cost-efficient 4. Easy genetic engineering 5. Well-established | 1. Limited post-translational modifications 2. No endogenous membrane structures for the synthesis of integral membrane proteins 3. Only native prokaryotic chaperones available: eukaryotic proteins might not be correctly folded | 1. Incorporation of non-canonical amino acids, hence protein engineering for the development of human therapeutics, modified enzymes, protein polymers, and ribosome display methods 2. Large-scale synthesis (up to 100 L) reaction volume 3. Industrial production of antibody–drug conjugates | [7, 165] [163] [1] [164]
| |
| Archaeal extract | 1. Extreme synthesis conditions like high temperature, so reduced inhibition of translation by secondary structures in mRNA 2. Synthesis of correctly folded thermostable proteins | 1. Low protein yield | 1. Synthesis of thermostable proteins | [49] [51]
|
| Protozoan extract | 1. Less expensive cultivation and lysate preparation 2. Good scalability 3. High solubility of synthesized proteins 4. Enhanced initiation of translation by addition of a special RNA sequence | 1. Types of post-translational modifications not well known 2. Less used or established 3. Low protein yield | 1. High-throughput analysis by PCR-based CFPS | [65] [63] [64]
|
| Yeast extract | 1. Ability to perform post-translational modifications like glycosylation 2. Simple and fast cultivation of cells for lysate preparation 3. Well-known in vivo system, so established methods for cell engineering available | 1. Low protein yield 2. No mammalian-like post-translational modifications | 1. Production of virus like particles for anti-viral drug research 2. Production of bioethanol and ( | [66] [177] [28, 72] [73] [74]
|
| Wheat germ extract | 1. Highly productive cell-free system, so high yield of complex proteins 2. Systems available for synthesis of disulfide-bridged proteins 3. Correct folding of many protein types, so high solubility of proteins 4. Well-known system | 1. Laborious and expensive lysate preparation 2. Limited post-translational modifications possible 3. No endogenous membrane structures 4. Low protein yield compare to prokaryotic and wheat germ systems | 1. Production of malaria proteins to characterize novel vaccine candidates 2. On-chip protein synthesis 3. High-throughput applications 4. Production of monoclonal antibodies against GPCRs 5. Investigation of translational processes (conformation analysis of ribosomes) | [7, 80] [4, 83] [86] [81] [20] [175]
|
| Tobacco BY-2 extract | 1. Fast and easy lysate preparation procedure 2. Glycosylation and disulfide-bridge formation are possible 3. Yield comparable to wheat germ extracts | 1. Limited evaluations of the system are available 2. Contain endogenous amino acids, so difficult to obtain good protein yield | Novel cell-free system High potential for future applications | [87] [88] [89]
|
| Insect cell extract | 1. Easy and fast lysate preparation 2. Post-translational modifications are possible (glycosylation, disulfide-bridge formation, lipidation, signal peptide cleavage phosphorylation) 3. Endogenous microsomes are available 4. Direct synthesis and integration of membrane proteins | 1. High cultivation costs | 1. GUV formation for membrane protein model to study biological processes 2. Engineering of proteins with integration of non-canonical amino acids 3. Automated production of membrane proteins | [92, 104] [95, 97] [17] [16] [103]
|
| Rabbit reticulocyte extract | 1. Well-established system 2. Mammalian system 3. Protein synthesis in the presences of supplemented, heterogeneous microsomes possible (e.g., canine pancreas microsomes) | 1. Low protein yield 2. Post-translational modifications only possible by supplementation with exogenous microsomes 3. Treatment of living animals required for lysate preparation | 1. Protein microarray technologies 2. Protein–molecule interaction studies 3. Display technologies 4. Screening technologies | [110] [111] [115] [117] [125]
|
| CHO cell extract | 1. Well-known and characterized cell line (often used for pharmaceutical in vivo protein production) 2. Contain endogenous microsomal structures 3. Mammalian post-translational modifications 4. Direct production of membrane proteins 5. Increase in protein yield by IRES-mediated translation initiation | 1. Low protein yield compared to prokaryotic cell-free systems 2. High cultivation cost 3. Robust cell line | 1. Novel cell-free system 2. High potential for future applications | [108] [130] [128]
|
| Extract from cultured human cell lines | 1. Optimal environment for correct folding and assembly of human proteins 2. Contain endogenous microsomal structures 3. Human-like post-translational modifications possible 4. Adapted codon usage to facilitate synthesis of high-molecular- weight proteins | 1. Low protein yield compared to prokaryotic cell-free systems 2. High cultivation cost 3. Laborious cultivation technologies are necessary (sensitive cells) | 1. Investigation of viral replication mechanisms; development of antiviral drugs | [135] [141] [143, 144] [136, 142] [107, 138] [130]
|